Introduction
It is important to establish the diagnosis of acute myocardial infarction (AMI) expeditiously so that an immediate treatment plan can be developed. However, rapidly diagnosing AMI is challenging because patients with possible AMI constitute a heterogeneous group. Many of these patients will have increased cardiac troponin (cTn) levels in the absence of AMI, especially with high-sensitivity cardiac troponin (hs-cTn) assays. 1, 2 Furthermore, although chest pain represents the most common presenting symptom, up to 40% of patients with non-ST segment elevation AMI present with dyspnoea or other non-specific symptoms. 3 The term 'high-sensitivity' reflects the assay's characteristics and two criteria have been proposed to define an hs-cTn assay: (a) the total imprecision at the 99th percentile should be ≤10% and (b) measurable concentrations above the assay's limit of detection and below the 99th percentile should be attainable for at least 50% of healthy people. 4 Novel rule-in strategies have recently been developed based on the use of hs-cTn assays and taking advantage of their increased analytical sensitivity and precision. The aim of this review is to provide a condensed summary of the key characteristics and performance measures of these strategies, including some important limitations, so physicians can select and apply the strategy that best suits their local needs.
Diagnostic process
AMI is diagnosed when there is an increase and/or decrease in cardiac biomarker values (preferably cTn) with at least one value >99th percentile of the upper reference limit (URL), together with symptoms and/or signs of ischaemia. 5 The diagnostic process for patients with possible AMI is summarized in Figures 1 and 2 . In low to intermediate risk patients, it is mandatory to wait to document a rising and/or falling pattern and, even if this is present, alternative (non-AMI) diagnoses should be considered. By contrast, for high-risk patients who present with typical symptoms and/or marked changes on an electrocardiogram, the finding of a clearly increased cTn value may be sufficient to make a working diagnosis of AMI. For defining risk, a risk stratification score (e.g. TIMI risk score, Grace Score or Heart score) is suggested. 6 A suggested management process for the evaluation of patients with typical symptoms is given in Figure 3 .
Defining delta changes
Using standard cTnI assays, increasing the delta values from ⩾10 to ⩾30% augmented the clinical specificity for the diagnosis of AMI while leaving the sensitivity unaltered. 7 The ROC-optimized relative delta change values for hs-cTnT were 117 and 243% within three and six hours in a selected small, high-risk cohort of patients with evolving AMI. 8 At the extreme end, Keller et al. 9 reported that a relative change of 250% at three hours in patients with an initial cTnI >99th percentile yielded the highest positive predictive value (95.8%). Reichlin et al. 10 tested the utility of absolute and relative delta changes of hs-cTnT for the early diagnosis of AMI and found that the performance of absolute delta changes was superior to relative delta changes. Other researchers have suggested that the improvement is predominantly seen in patients who present late with increased baseline values. 1 Regardless of whether relative or absolute delta values are used, higher delta values increase the specificity for ruling-in AMI, but at the cost of clinical sensitivity and vice versa. It should also be made clear that delta values are assay-dependent. 11 The European Society of Cardiology (ESC)-Acute Cardiovascular Care Association Study Group on Biomarkers recently proposed various criteria for carrying out the additional studies needed in this area. 11
Specific subgroups
The universal definition for myocardial infarction mandates the use of sex-specific cut-off values. 5 Studies using hs-cTnI assays have recently reported that sex-dependent cut-off values have little effect in men, but more in women, 12, 13 although Cullen et al. 13 concluded that the 'net-effect across the whole ED population with possible cardiac chest pain is minimal'. Another study showed that this is also true for conventional cTn assays. 14 Other workers have suggested age-related cut-offs 15 because putatively normal cTn levels are age-dependent. However, underlying comorbidities were common in these studies and may explain a large portion of the increases observed. 16 
Strategies for rapid rule-in of AMI using hs-cTn

ESC guidelines three-hour strategy
The ESC guidelines 6, 17, 18 recommend that hs-cTn should be tested at presentation and 3 h later in patients with acute chest pain; AMI is diagnosed when at least one value is >99th percentile URL and with a rising/falling pattern in the values. Hence even if the initial hs-cTn value is >99th percentile URL, only a subsequent change is considered diagnostic. However, the diagnosis of AMI can be made in patients with a 'highly abnormal' hs-cTn (the values used are assay-dependent) on admission in the context of a 'typical presentation'.
One-hour algorithm and two-hour algorithm
These algorithms include both a rule-in and a rule-out component (Table 1 ). For rule-in, they use a combination of a high cut-off value for hs-cTn on admission, which is substantially higher than the 99th percentile level, and absolute delta changes over one and two hours. These strategies have shown promising results in observational studies. 10, [19] [20] [21] [22] [23] Table 1 summarizes the study characteristics and the performance measures of the algorithms. It is important to note that a significant proportion of patients will remain in the 'no rule-out, no rule-in zone' after one and two hours and that these patients will need further testing before AMI can be ruled in or out. 
Important caveats in evaluating reported biomarker protocols to rule-in AMI
• Most studies have tested the use of biomarkers retrospectively in selected subgroups of patients with possible AMI, and mostly in those patients with chest discomfort. Applying these algorithms in 'all comers', including those patients with symptoms other than chest pain, will make a huge difference in the frequency of AMI and the ability to extrapolate the approach to all patients. • The number of patients who present very early (one to two hours after the onset of symptoms) is too limited in most studies to be sure that the criteria for ruling-out and ruling-in do not overlap. • The gold standard diagnosis varies across the studies.
The common use of less sensitive local criteria exaggerates the impact of a more sensitive assay on the time it takes to detect diagnostic biomarker signals. 24 The use of one hs-cTn assay to compare with another biases in favour of the gold standard assay. Thus a critical look at the gold standard diagnosis is crucial to understanding these studies. • The proposed assay-specific absolute values in the one-hour and two-hour algorithms will perform differently depending on the pre-test probability of AMI and the precision of the assays. Therefore they require further validation, particularly in elderly patients, those with impaired renal function and those who present early after the onset of symptoms. • Increases in hs-cTn as late as six hours after the onset of symptoms have been described in a small (1%) number of patients. • There is concern about whether the assays have adequate precision to make some of the distinctions in the change criteria proposed. • Structured and validated clinical pathways for the significant proportion of patients in the 'no rule-out, no rule-in zone' are needed.
Summary: Critical clinical concepts
• New hs-cTn assay-specific strategies for rapid rulein of AMI, based on a combination of a high initial cut-off and absolute delta values over one or two hours, have been evaluated in observation studies.
They can be used as long as the caveats elucidated in this paper are clear and, moreover, each institution should select and apply the strategy that best suits their local needs. • The proposed cut-off and delta values are assay-specific. • The algorithms should always be used in conjunction with all available clinical information.
• Structured clinical pathways for the significant proportion of patients in the 'no rule-out, no rule-in zone' have to be established in each institution. These pathways should include further observation, repeated measurements of cTn and appropriate imaging tests (see Figure 1 ). 
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